Prime Medicine, Inc. $PRME

What the company doesAI summary of filing

Prime Medicine is a clinical-stage biotechnology company developing genetic medicines based on Prime Editing, a gene editing technology that makes targeted modifications to DNA without creating double-stranded breaks. The company is advancing a pipeline of programs targeting genetic diseases, including PM359 for chronic granulomatous disease (an ex vivo program in clinical development), PM577 for Wilson Disease (planned IND submission in the first half of 2026), PM647 for alpha-1 antitrypsin deficiency (planned IND submission in mid-2026), and early-stage programs in cystic fibrosis. Prime Medicine generates revenue through milestone payments and royalties from collaborations, including a partnership with Bristol-Myers Squibb valued at over $3.5 billion in potential milestones and funding from the Cystic Fibrosis Foundation. [10-K 2026-03-03]

Segments: PM359 (Chronic Granulomatous Disease, ex vivo), PM577 (Wilson Disease, in vivo), PM647 (Alpha-1 Antitrypsin Deficiency, in vivo), Cystic Fibrosis Program (in vivo)